SOSV

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

Level Zero Health focuses on advanced biosensor technology to collect new types of data by combining biochemistry and nanotechnology.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

LightHearted AI is an AI-driven remote cardiovascular diagnostics tool designed for the rapid, precise, and cost-effective detection of heart conditions.

MedIQ is an integrated virtual care platform providing on-demand healthcare at the point of need. MedIQ redefines healthcare through a digitally enabled, cashless, hybrid healthcare ecosystem. MedIQ makes high-quality, modernized healthcare and wellness available to everyone.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

OpenShelf, founded in 2023, develops an inventory automation system aimed at optimizing contact lens management for optometrists. The company offers flexible robotic solutions that can handle, sort, and dispense thousands of unique contact lens boxes. This technology allows optometrists to gain valuable insights into their inventory, such as when to reorder specific prescriptions and the frequency of stock replenishment at their practice. By streamlining the contact lens inventory process, OpenShelf enhances operational efficiency and supports better patient care.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Dia has invented an electrochemical sensor that can measure a wide variety of chemical biomarkers non-invasively in saliva or sweat. The data is sent via Bluetooth to an app on the user’s smartphone and analyzed in real-time. From the app, it can be securely sent to a third party. To date, we have measured hormones, electrolytes, neurotransmitters and metabolites. At DIA, we let the biology dictate which analyte we put on which platform – our wearable arm sleeve for sweat or our table-top device for saliva – because some biomarkers, such as cortisol fluctuate throughout the day and need to be monitored through a wearable sensor, while others, such as creatinine are more suitable to a daily saliva test.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, founded in 2011. The company specializes in developing advanced diagnostic solutions that utilize mass spectrometry technology to analyze biomarkers associated with complex diseases. Its primary focus is on providing predictive diagnoses for pre-eclampsia in early pregnancy through a blood test that assesses the risk of this condition, which can lead to serious complications such as hypertension and restricted blood flow to the fetus. Metabolomic Diagnostics has established a pipeline for identifying diagnostic biomarker panels and translating these findings into clinical assays suitable for use in laboratory settings, thus enabling effective disease diagnosis and risk prediction.

All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.

Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Untap Health has developed a pathogen monitoring platform focused on enhancing community health by detecting infections before they escalate into outbreaks. The platform analyzes wastewater samples from various sources, including commercial sites, schools, and wastewater treatment facilities, to identify viruses present in sewage. By leveraging high-frequency data, Untap provides early warnings of potential health incidents, facilitating timely interventions. This non-invasive and anonymized approach enables communities to maintain cleanliness and safety, effectively contributing to public health monitoring and management.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

ChektAhora specializes in providing at-home testing kits for sexually transmitted infections (STIs) and other contagious diseases, including respiratory viruses like influenza and COVID-19. The company offers a technology-enabled platform that allows customers to access confidential and convenient health tests without the discomfort of traditional testing methods. By utilizing advanced testing techniques such as PCR, antigens, and antibodies, ChektAhora aims to deliver laboratory-quality results directly to individuals in Latin America, ensuring a pain-free experience.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

ChronosDx is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics. The firm focuses on creating bioassay technology tailored for diagnostics, drug screening, and development. ChronosDx develops high-performance, cost-effective, and scalable technology that effectively detects various biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This innovative platform enables medical professionals to monitor biomarkers both in-line and in vivo, enhancing the capabilities of healthcare diagnostics.

Paragon Pure is a food company focused on developing natural ingredients that cater to contemporary dietary needs. The firm specializes in producing a healthy and sustainable structured fat and flavor system derived from upcycled rice bran, particularly for use in alternative proteins. By leveraging expertise in flavor encapsulation, process engineering, and physical chemistry, Paragon Pure aims to create genuine ingredients that deliver natural flavors, colors, and nutrients in wholesome foods. This approach enables consumers to fully enjoy the diverse flavors of various spices while adhering to healthier eating practices.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

Kinexcs is an AI-driven health platform and wearables company focused on enhancing mobility and improving quality of life for individuals with musculoskeletal conditions. It addresses issues of incomplete recovery and patient compliance through its innovative digital therapy solutions, which are both cost-effective and convenient. The company has developed KIMIA, the world's first continuous knee health monitor, combined with an AI-based digital therapist that facilitates access to therapy. Kinexcs collaborates with key opinion leaders and major public hospitals in Singapore on various clinical projects, while also offering its products through orthopedic surgeons and significant implant manufacturers. The integration of continuous monitoring and real-time exercise guidance supports patients in managing their conditions effectively.

PONS develops artificial intelligence models to enhance ultrasound imaging, unveiling visual insights invisible on conventional devices. Our deep learning algorithms elevate risk assessment of disease progress happening outside the hospital settings and our patented image enhancement system increases basic ultrasound images to provide expert-level scan resolution, tissue contrast, and noise reduction without requiring expensive new hardware. PONS is an AI-integrated machine vision system for mobile ultrasound technologies that lets doctors perform medical imaging remotely. PONS autonomously carries out the risk assessment, smart image processing, segmentation, and reporting of medical images to the doctor. By using PONS, doctors can monitor patients for critical health, women & child health complications anywhere and instantly

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Flowbio is a wellness and fitness services company that specializes in hydration monitoring for athletes, including triathletes, cyclists, and runners. The firm has developed a real-time hydration biosensor platform that utilizes a wearable, non-invasive patch to analyze sweat and assess key biomarkers, focusing initially on electrolytes and total body fluid loss. This technology enables users to receive personalized recommendations to enhance their athletic performance by better managing their hydration levels.

Aksense is a biotechnology company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. The company has created a portable rapid infection diagnostic biosensor designed to enhance healthcare by providing high-quality and safe care. Aksense's technology aims to improve antibiotic prescribing practices and public health outcomes by enabling early detection and treatment of infections. This approach reduces the spread of infections and improves patient outcomes, allowing users to achieve faster recovery through cost-effective molecular testing solutions.

Portable Diagnostic Systems develops a microfluidics-based drug testing platform for law enforcement that takes the guesswork out of impaired driving traffic stops. The company was founded in August 2019.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, founded in 2011. The company specializes in developing advanced diagnostic solutions that utilize mass spectrometry technology to analyze biomarkers associated with complex diseases. Its primary focus is on providing predictive diagnoses for pre-eclampsia in early pregnancy through a blood test that assesses the risk of this condition, which can lead to serious complications such as hypertension and restricted blood flow to the fetus. Metabolomic Diagnostics has established a pipeline for identifying diagnostic biomarker panels and translating these findings into clinical assays suitable for use in laboratory settings, thus enabling effective disease diagnosis and risk prediction.

Zennea Technologies is a medical device company based in Surrey, Canada, specializing in the development of therapeutic wearables aimed at reducing snoring and improving overall health through enhanced sleep quality. The company's flagship product, ZENS, is a comfortable and discreet wearable designed to address chronic snoring and mild obstructive sleep apnea at its source. Zennea conducts clinical trials to validate the effectiveness of its technology, which not only targets snoring but also tracks sleep quality, assisting users in making informed decisions to enhance their sleep health.

FoodMarble is a company that addresses the challenges faced by nearly one billion individuals with disruptive digestive symptoms. Its flagship product, AIRE, is a personal breath analyzer designed to help users identify which foods are best suited to their unique digestive systems. By utilizing a handheld device and a companion application, AIRE allows individuals to monitor their digestion in real time, leveraging techniques commonly employed in gastroenterology. This innovative approach empowers users to develop personalized diets that can alleviate discomfort and improve their overall well-being. Since its inception, FoodMarble has garnered significant interest, receiving over $500,000 in pre-orders prior to the commencement of device shipments in late 2017. The company aims to create the first comprehensive dataset of its kind, further enhancing users' ability to manage their digestive health.

PhableCare creates an ecosystem of patients, doctors, hospitals, health devices, insurance, and patient care service providers. In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring.

Conan MedTech develops a rapid POC diagnostic test for concussions. The company aims to revolutionize the mild traumatic brain injury diagnosis market to allow sport medicine doctors and athletic coaches and trainers to make a decision on the sideline during a game. Conan MedTech was founded in 2020 and is based in Ithaca, New York.

Conan MedTech develops a rapid POC diagnostic test for concussions. The company aims to revolutionize the mild traumatic brain injury diagnosis market to allow sport medicine doctors and athletic coaches and trainers to make a decision on the sideline during a game. Conan MedTech was founded in 2020 and is based in Ithaca, New York.

Harae Dx Corp. is a medical diagnostics company specializing in cancer detection. The company has created an automated, portable system that facilitates early cancer diagnosis by identifying cancer biomarkers directly, eliminating the need to send samples to third-party laboratories. This innovative approach reduces the risk of human error in processing and enhances the speed of results, allowing healthcare professionals to detect and treat cancer more effectively and affordably. Harae Dx's compact and cost-efficient solution aims to improve patient outcomes through timely and accurate diagnostics.

PONS develops artificial intelligence models to enhance ultrasound imaging, unveiling visual insights invisible on conventional devices. Our deep learning algorithms elevate risk assessment of disease progress happening outside the hospital settings and our patented image enhancement system increases basic ultrasound images to provide expert-level scan resolution, tissue contrast, and noise reduction without requiring expensive new hardware. PONS is an AI-integrated machine vision system for mobile ultrasound technologies that lets doctors perform medical imaging remotely. PONS autonomously carries out the risk assessment, smart image processing, segmentation, and reporting of medical images to the doctor. By using PONS, doctors can monitor patients for critical health, women & child health complications anywhere and instantly

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Paragon Pure is a food company focused on developing natural ingredients that cater to contemporary dietary needs. The firm specializes in producing a healthy and sustainable structured fat and flavor system derived from upcycled rice bran, particularly for use in alternative proteins. By leveraging expertise in flavor encapsulation, process engineering, and physical chemistry, Paragon Pure aims to create genuine ingredients that deliver natural flavors, colors, and nutrients in wholesome foods. This approach enables consumers to fully enjoy the diverse flavors of various spices while adhering to healthier eating practices.

Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

Untap Health has developed a pathogen monitoring platform focused on enhancing community health by detecting infections before they escalate into outbreaks. The platform analyzes wastewater samples from various sources, including commercial sites, schools, and wastewater treatment facilities, to identify viruses present in sewage. By leveraging high-frequency data, Untap provides early warnings of potential health incidents, facilitating timely interventions. This non-invasive and anonymized approach enables communities to maintain cleanliness and safety, effectively contributing to public health monitoring and management.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Neurode is focused on the development of a non-invasive wearable headset aimed at enhancing cognitive performance for individuals with neurological conditions, particularly ADHD. This innovative device employs electrical stimulation to address the imbalances in brain activity commonly associated with ADHD. Alongside the headset, Neurode offers a companion application that monitors users' progress and shares improvements with healthcare professionals. This drug-free approach seeks to alleviate symptoms such as working memory deficits, attention challenges, and impulse control issues, ultimately enabling better management of cognitive performance for users.

Caura Ltd. is a London-based company established in 2018 that specializes in vehicle management solutions. The company offers a platform that enables drivers to efficiently handle various aspects of car ownership, including payments for parking, tolls, congestion charges, MOTs, vehicle tax, and insurance. Additionally, Caura provides a product called Caura Protect, which allows users to purchase and manage motor insurance through a network of insurers. The company also focuses on developing microelectronic devices that monitor health metrics such as lactate and glucose levels, along with heart-rate and accelerometry data. Furthermore, Caura creates application software that connects to these devices to generate reports and analyze the collected data.

Harae Dx Corp. is a medical diagnostics company specializing in cancer detection. The company has created an automated, portable system that facilitates early cancer diagnosis by identifying cancer biomarkers directly, eliminating the need to send samples to third-party laboratories. This innovative approach reduces the risk of human error in processing and enhances the speed of results, allowing healthcare professionals to detect and treat cancer more effectively and affordably. Harae Dx's compact and cost-efficient solution aims to improve patient outcomes through timely and accurate diagnostics.

Neurocess offers services as a wearable technology product that increases the training performance and reduces the risk of injury by analyzing the muscle of professional athletes.

Kite Medical has created an innovative device designed to detect kidney reflux in children experiencing urinary tract infections. This non-invasive diagnostic solution simplifies the detection process, eliminating the need for complex procedures and hospital visits. Kidney reflux, the most common urological disorder in childhood, affects up to three percent of young children, particularly those aged six months to five years. While the condition may resolve as children grow, undiagnosed and untreated cases can lead to serious consequences, including permanent kidney damage and kidney failure. By providing a straightforward and accessible means of diagnosis, Kite Medical aims to improve the management of this prevalent condition in pediatric patients.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

PhableCare creates an ecosystem of patients, doctors, hospitals, health devices, insurance, and patient care service providers. In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Flowbio is a wellness and fitness services company that specializes in hydration monitoring for athletes, including triathletes, cyclists, and runners. The firm has developed a real-time hydration biosensor platform that utilizes a wearable, non-invasive patch to analyze sweat and assess key biomarkers, focusing initially on electrolytes and total body fluid loss. This technology enables users to receive personalized recommendations to enhance their athletic performance by better managing their hydration levels.

FoodMarble is a company that addresses the challenges faced by nearly one billion individuals with disruptive digestive symptoms. Its flagship product, AIRE, is a personal breath analyzer designed to help users identify which foods are best suited to their unique digestive systems. By utilizing a handheld device and a companion application, AIRE allows individuals to monitor their digestion in real time, leveraging techniques commonly employed in gastroenterology. This innovative approach empowers users to develop personalized diets that can alleviate discomfort and improve their overall well-being. Since its inception, FoodMarble has garnered significant interest, receiving over $500,000 in pre-orders prior to the commencement of device shipments in late 2017. The company aims to create the first comprehensive dataset of its kind, further enhancing users' ability to manage their digestive health.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Magellan Life Sciences Ltd. is a synthetic biology company based in London, United Kingdom, specializing in the development of plant-based proteins for the food and beverage industries. Established in 2018, the company focuses on creating innovative protein sweeteners, including brazzein, utilizing its proprietary protein engineering and expression platforms. These novel protein-based molecules are designed to offer non-calorific alternatives that address sugar content and associated health concerns. By providing advanced solutions for the food, health, and nutrition sectors, Magellan Life Sciences aims to meet the growing demand for healthier ingredients in consumer products.

Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

FoodMarble is a company that addresses the challenges faced by nearly one billion individuals with disruptive digestive symptoms. Its flagship product, AIRE, is a personal breath analyzer designed to help users identify which foods are best suited to their unique digestive systems. By utilizing a handheld device and a companion application, AIRE allows individuals to monitor their digestion in real time, leveraging techniques commonly employed in gastroenterology. This innovative approach empowers users to develop personalized diets that can alleviate discomfort and improve their overall well-being. Since its inception, FoodMarble has garnered significant interest, receiving over $500,000 in pre-orders prior to the commencement of device shipments in late 2017. The company aims to create the first comprehensive dataset of its kind, further enhancing users' ability to manage their digestive health.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Mobio Interactive Inc. specializes in creating digital tools that enhance mental health and well-being for both consumers and clinical populations. Founded in 2014 and headquartered in Toronto, Canada, with additional offices in Zurich, Switzerland, and Shanghai, China, the company has developed applications such as Am Mindfulness, Wildflowers Mindfulness, and Actify Mindfulness. These applications provide medical-grade mindfulness training while objectively measuring the effectiveness of mindfulness practices through advanced analytics. Mobio's AI-powered digital theragnostic platform delivers clinically validated psychotherapy programs tailored to individual patients, utilizing digital biomarkers to assess human brain states without the need for wearable devices. The platform ensures secure and private interactions for users, allowing them to engage with mental health resources from anywhere in the world.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Hisens is a company focused on developing an innovative underwearable sensor designed to monitor erectile dysfunction. The product includes a mobile application that works in conjunction with wearable sensors to collect physiological data from users in real time while they sleep. This technology allows for professional data analysis and personalized treatment options. By enabling users to track their own data, treatment progress, rehabilitation degrees, and the effectiveness of various treatment options, Hisens facilitates better communication between patients and their healthcare providers.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Flowbio is a wellness and fitness services company that specializes in hydration monitoring for athletes, including triathletes, cyclists, and runners. The firm has developed a real-time hydration biosensor platform that utilizes a wearable, non-invasive patch to analyze sweat and assess key biomarkers, focusing initially on electrolytes and total body fluid loss. This technology enables users to receive personalized recommendations to enhance their athletic performance by better managing their hydration levels.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, founded in 2011. The company specializes in developing advanced diagnostic solutions that utilize mass spectrometry technology to analyze biomarkers associated with complex diseases. Its primary focus is on providing predictive diagnoses for pre-eclampsia in early pregnancy through a blood test that assesses the risk of this condition, which can lead to serious complications such as hypertension and restricted blood flow to the fetus. Metabolomic Diagnostics has established a pipeline for identifying diagnostic biomarker panels and translating these findings into clinical assays suitable for use in laboratory settings, thus enabling effective disease diagnosis and risk prediction.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

OaCP specializes in healthcare technology focused on enhancing cancer diagnosis through innovative molecular in vitro diagnostics. The company offers patented chemical reagents that significantly reduce both the time and cost associated with DNA testing for cancer, achieving a 97% reduction in time and a 50% reduction in costs. Operating within the competitive USD 1 billion in situ hybridization market, OaCP has recorded USD 100,000 in sales and maintains a strong customer retention rate and gross margin. Its distribution network spans nearly 15 countries, serving hospitals and research and development centers. The company has participated in the RebelBio Accelerator program and secured funding of USD 330,000 from SOS Venture. OaCP has received recognition in various international competitions, particularly in Hong Kong and China. Currently, the company seeks an investment of EUR 2 million to further expand its market presence and develop its diagnostic technology, ultimately aiming to improve the quality of life for cancer patients.

This technology marks a start to real-time bacteria detection. Currently, bacteria monitoring is done through manual weekly or monthly samples that are sent to the lab for analysis. Normally, lab analysis takes around 18 - 72 hours until results are available. Ecoli Sense wants to innovate real-time monitoring by making this technology available for bacteria detection.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Sepsitron specializes in medical diagnostic technology that enables the rapid detection of blood infections caused by various pathogens, including viral, bacterial, parasitic, and fungal agents. The company's innovative approach utilizes unique biomarkers, microfluidics, and advanced electronics to provide a diagnostic device that is significantly faster and more cost-effective than traditional methods. Sepsitron's tests require no sample pre-processing and can analyze whole blood samples, allowing for the precise identification of multiple pathogens from a single test. This technology aims to enhance the speed and effectiveness of disease detection and treatment for healthcare professionals. Sepsitron has garnered support from prominent startup accelerators, positioning itself as a leader in point-of-care diagnostics.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.